Similar Stories to Birth-control Drugmaker Evofem Biosciences Has Spiked 240% Since The Supreme Court's Decision To Overturn Roe Vs. Wade on Bing News

The US Supreme Court is seen behind fences in Washington, DC, on May 11, 2022.Stefani Reynolds/AFP via Getty Images Evofem Biosciences shares spiked 240% in the past two days following the overturning of Roe vs. Wade. The drugmaker owns Phexxi, one of the few non-hormonal birth control options available. "I think it's insane that women have not had an option like this before now," Evofem CEO Saundra Pelletier said in a 2021 interview to the New York Times. Evofem Biosciences shares extended their two-day gain to 240% on Monday, continuing a surge that began in the wake of the Supreme Court's decision to overturn Roe vs.